Medication info
Rosatol Plus Tablet

Rosatol Plus Tablet

Prescription medicationTablet
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Hanpung Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201904374 · Approved 2019.06.26

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall antihypertensive effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in these patients because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be administered with this combination.
Children's dosage
Pediatric patients (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Hanpung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

Used for hypertension that is not adequately controlled with monotherapy.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall antihypertensive effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in these patients because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be administered with this combination.

Children's dosage

Pediatric patients (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to certain patients, for instance, those allergic to this medication or its components, patients with severely impaired kidney function, severe liver impairment, women who are pregnant or may become pregnant, and those with specific electrolyte abnormalities. Additionally, patients with low blood pressure or problems with renal blood vessels, those with a history of liver disease, diabetes or gout, and the elderly should use this medication with caution, and sun exposure should be limited due to an increased risk of skin cancer, while skin condition should be monitored frequently. During the use of this medication, electrolyte imbalances, especially changes in potassium levels, should be carefully monitored, as symptoms of excessively low blood pressure, dizziness, or drowsiness may occur, requiring caution while driving or operating machinery. As this medication may interact with other drugs, especially potassium-sparing diuretics, potassium supplements, non-steroidal anti-inflammatory drugs, and lithium preparations, consultation with a physician is advised if taken in combination. This medication also requires caution in nursing women, and it is necessary to decide whether to discontinue breastfeeding or consult a doctor prior to administration. The safety of this medication in children and adolescents has not been established, thus it is not administered to this age group. If any abnormal symptoms appear during administration, consult a healthcare professional immediately, especially in cases of suspected allergic reactions such as skin rash, difficulty breathing, or severe dizziness; discontinue use immediately.

Side effects

  • Abdominal pain
  • edema
  • swelling
  • palpitations
  • lumbar pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
Show 125 more
  • angioedema
  • skin detachment
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • reduced libido
  • memory impairment
  • migraine
  • neuralgia
  • panic disorder
  • paresthesia
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste alteration
  • tinnitus
  • erectile dysfunction
  • enuresis
  • pollakiuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • salivary gland inflammation
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle twitching
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that blocks light, and the storage temperature should be maintained between 1 degrees and 30 degrees Celsius at room temperature. By storing it this way, the efficacy of the medication can be safely maintained.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.